Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Bioadaptives (BDPT) Return on Equity (2019 - 2025)

Historic Return on Equity for Bioadaptives (BDPT) over the last 7 years, with Q3 2025 value amounting to 0.88%.

  • Bioadaptives' Return on Equity rose 6500.0% to 0.88% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.88%, marking a year-over-year increase of 6500.0%. This contributed to the annual value of 0.45% for FY2024, which is 1900.0% up from last year.
  • According to the latest figures from Q3 2025, Bioadaptives' Return on Equity is 0.88%, which was up 6500.0% from 0.59% recorded in Q2 2025.
  • Over the past 5 years, Bioadaptives' Return on Equity peaked at 0.99% during Q4 2021, and registered a low of 0.23% during Q3 2024.
  • For the 5-year period, Bioadaptives' Return on Equity averaged around 0.56%, with its median value being 0.57% (2022).
  • Per our database at Business Quant, Bioadaptives' Return on Equity tumbled by -4400bps in 2023 and then surged by 6500bps in 2025.
  • Quarter analysis of 5 years shows Bioadaptives' Return on Equity stood at 0.99% in 2021, then plummeted by -42bps to 0.57% in 2022, then crashed by -51bps to 0.28% in 2023, then skyrocketed by 47bps to 0.41% in 2024, then skyrocketed by 114bps to 0.88% in 2025.
  • Its Return on Equity stands at 0.88% for Q3 2025, versus 0.59% for Q2 2025 and 0.54% for Q1 2025.